Saskatchewan Uranium Explorer Hits 8760 cps over 7.4m at New Q24 Target
Source: Streetwise Reports 09/22/2026
Purepoint Uranium reports strong radiometric results from the first hole at Q24 in the Dorado JV, including 7.4 meters averaging 8760 cps. See why this expands the Athabasca Basin project ahead of 2027 plans.
Purepoint Uranium Group Inc. (PTU:TSX.V; PTUUF:OTCQB) delivered encouraging early results from its 2026 summer drill program at the Dorado joint venture in Saskatchewan’s Athabasca Basin. The first hole into the new Q24 target produced a 7.4-meter radioactive interval averaging 8,760 counts per second right at the unconformity.
This intersection, which included a 0.5-meter section reaching 38,710 cps, immediately positions Q24 as a third distinct area of interest alongside the existing Nova discovery and the Q23 target.
Why the Q24 Result Matters for Retail Investors Right Now
The Athabasca Basin remains one of the world’s premier districts for high-grade uranium deposits. Radioactivity readings at the unconformity, combined with alteration and structural disruption, are classic signs that explorers look for when testing new ground.
Q24 is a separate target area from Nova and Q23 and was tested using a strong ground electromagnetic conductor.
Key Investor Takeaways
- The first hole at Q24 returned 7.4 meters, averaging 8,760 cps, including 0.5 meters at 38,710 cps, establishing Q24 as a new priority target at Dorado.
- Dorado now has three distinct target areas—Nova, Q23, and Q24—with drilling identifying uranium mineralization at Nova and elevated radioactivity at Q23 and Q24.
- Assays from the full 3,669-meter summer campaign are still pending and will provide the next concrete data point.
- Red Cloud analyst David Talbot kept a Buy (Speculative) rating and CA$1.15 target on Purepoint while highlighting the broader uranium market tailwinds.
- Spot uranium was near US$90 per pound in mid-September, while TradeTech’s Long-Term Uranium Price Indicator reached an 18-year high of US$97 per pound on June 30.
Purepoint’s Position Through the Dorado Joint Venture
IsoEnergy Ltd. (ISO:TSX; ISOU:NYSEAMERICAN) holds a 50 percent interest and acts as a strategic partner. Purepoint operates the project.
The 50/50 joint venture allows Purepoint and IsoEnergy to share ownership and advance exploration at Dorado together, with Purepoint acting as operator. The project sits along the eastern margin of the Athabasca Basin, where structural corridors have historically hosted unconformity-related uranium deposits.
Key Assets and Next Catalysts at Dorado
The Nova discovery already shows a roughly one-kilometer mineralized trend. Earlier drilling there returned grades up to 8.1 percent U3O8 over 0.4 meters.
The 2026 program tested additional corridors at Q23 and the newly drilled Q24. Hole PG26-10 at Q23 also intersected several intervals of elevated radioactivity in altered sandstone and basement rocks. The results from Nova, Q23, and Q24 will help guide future exploration at Dorado as the joint venture integrates its drilling and geophysical data.
Broader Uranium Market Timing
The World Nuclear Association’s World Nuclear Outlook Report 2026 projects global nuclear capacity could reach 1,457 GWe by 2050 in a high-growth scenario. An August 25 OilPrice report noted spot prices near US$89 per pound and linked strength to a structural supply shortfall that new mines cannot quickly fill.
A late-2025 Mining.com outlook highlighted AI-driven electricity demand as an additional long-term driver. Spot uranium traded near US$90 per pound in mid-September 2026, while TradeTech’s long-term price indicator reached an 18-year high of US$97 per pound as of June 30.
Analyst Views and Valuation Context
Red Cloud analyst David Talbot maintained a Buy rating and CA$27.15-per-share target price for ISO, along with a Buy (Speculative) rating and CA$1.15-per-share target price for PTU.
Talbot described the Q24 radiometric response as encouraging and noted that the first-hole result supports the exploration model. He also pointed out that Purepoint shares remain near their 52-week low despite the expanding prospectivity at Dorado.
Share Structure and Near-Term Events1
Strategic investor IsoEnergy owns 13 percent, insiders hold 2 percent, and institutions own 17 percent. [OWNERSHIP_CHART-183]
Market capitalization stands at CA$28.3 million with 82.03 million shares outstanding. The stock trades in a 52-week range of CA$0.31 to CA$0.85.
Upcoming catalysts include pending summer assays, completion of the MobileMT structural interpretation, and 2027 exploration planning at Dorado.
Common Questions from Investors
What is the significance of the 7.4-meter interval at Q24? It marks the combination of strong radioactivity at the unconformity, significant alteration, structural disruption, and graphitic basement rocks that Purepoint has identified as important exploration features in the district.
How does Q24 differ from Nova and Q23? Q24 is a separate target area from Nova and Q23, giving the joint venture another priority area for follow-up exploration.
When will assay results be available? Laboratory assays from the 3,669-meter summer program remain pending and will be reported when they become available.
What is the current uranium price environment? Spot prices sit near US$90 per pound while TradeTech’s Long-Term Uranium Price Indicator reached an 18-year high of US$97 per pound.
What are the main catalysts ahead? Pending assays, the MobileMT survey interpretation, 2027 drill planning at Dorado, and IsoEnergy’s Tony M production decision.
The combination of a new high-priority target, multiple corridors showing radioactivity, and a constructive uranium market backdrop gives retail investors a clear framework for monitoring Purepoint’s progress through the remainder of 2026 and into 2027.
[SMNLINSERT]
Important Disclosures:
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
( Companies Mentioned: ISO:TSX;ISOU:NYSE American, PTU:TSX.V; PTUUF:OTCQB, )
Source: https://www.streetwisereports.com/article/2026/09/22/saskatchewan-uranium-explorer-hits-8760-cps-over-7-4m-at-new-q24-target.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

